Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ciclopirox - Atlas Molecular Pharma

Next Previous
Drug Profile

Ciclopirox - Atlas Molecular Pharma

Alternative Names: AMP L2.7. D7; ATL-001 - Atlas Molecular Pharma; Ciclopirox olamine - Atlas Molecular Pharma; L2.7.D7

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atlas Molecular Pharma
  • Class Antifungals; Proteins; Pyridones; Small molecules
  • Mechanism of Action Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Erythropoietic porphyria
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Erythropoietic porphyria

Most Recent Events

  • 17 Jun 2025 Atlas Molecular Pharma plans a phase I/II trial for Congenital erythropoietic porphyria (PO) in November 2025 (NCT07024316)
  • 15 Apr 2024 Chemical structure information added
  • 08 Apr 2024 Atlas Molecular Pharma completes a phase I trial in Erythropoietic porphyria (In volunteers) in USA (NCT05647343)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top